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Insect cells are superior to Escherichia coli in
producing malaria proteins inducing IgG
targeting PfEMP1 on infected erythrocytes
Michala E Victor1†, Anja Bengtsson1†, Gorm Andersen1, Dominique Bengtsson1, John P Lusingu1,2,
Lasse S Vestergaard1, David E Arnot1,3, Thor G Theander1, Louise Joergensen1, Anja TR Jensen1*
Abstract
Background: The PFD1235w Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) antigen is
associated with severe malaria in children and can be expressed on the surface of infected erythrocytes (IE)
adhering to ICAM1. However, the exact three-dimensional structure of this PfEMP1 and its surface-exposed
epitopes are unknown. An insect cell and Escherichia coli based system was used to express single and double
domains encoded by the pfd1235w var gene. The resulting recombinant proteins have been evaluated for yield
and purity and their ability to induce rat antibodies, which react with the native PFD1235w PfEMP1 antigen
expressed on 3D7PFD1235w-IE. Their recognition by human anti-malaria antibodies from previously infected
Tanzanian donors was also analysed.
Methods: The recombinant proteins were run on SDS-PAGE and Western blots for quantification and size
estimation. Insect cell and E. coli-produced recombinant proteins were coupled to a bead-based Luminex assay to
measure the plasma antibody reactivity of 180 samples collected from Tanzanian individuals. The recombinant
proteins used for immunization of rats and antisera were also tested by flow cytometry for their ability to surface
label 3D7PFD1235w-IE.
Results: All seven pAcGP67A constructs were successfully expressed as recombinant protein in baculovirus-infected
insect cells and subsequently produced to a purity of 60-97% and a yield of 2-15 mg/L. By comparison, only three
of seven pET101/D-TOPO constructs expressed in the E. coli system could be produced at all with purity and yield
ranging from 3-95% and 6-11 mg/L. All seven insect cell, but only two of the E. coli produced proteins induced
antibodies reactive with native PFD1235w expressed on 3D7PFD1235w-IE. The recombinant proteins were recognized
in an age- and transmission intensity-dependent manner by antibodies from 180 Tanzanian individuals in a bead-
based Luminex assay.
Conclusions: The baculovirus based insect cell system was distinctly superior to the E. coli expression system in
producing a larger number of different recombinant PFD1235w protein domains and these were significantly easier
to purify at a useful yield. However, proteins produced in both systems were able to induce antibodies in rats,
which can recognize the native PFD1235w on the surface of IE.
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Background
Malaria remains a devastating infectious disease, with
the parasite Plasmodium falciparum being responsible
for killing approximately one million children below the
age of five each year [1]. Development of an effective
malaria vaccine would have a profound impact on the
control of the disease as drug resistance toward afford-
able, effective drugs continues to emerge. However,
since nearly 60% of hypothetical proteins in the parasite
genome are of unknown function, much needs to be
learned about the biology of the parasite. In particular,
identifying parasite antigens that elicit long-lasting pro-
tective immune response has proven very difficult [2].
In the discovery and characterization of new vaccine
candidates, bioinformatics tools are useful, but protein
function and structure cannot be definitely determined
from exclusively in silico experiments. However, suffi-
cient quantities of the “protein of interest” cannot
usually be isolated from either host infection or in vitro
culture host. Therefore, heterologous expression of solu-
ble and functional parasite proteins is key to progress
toward identification of new vaccine candidates.
The classic genetic model bacterium, Escherichia coli,
is still a preferred organism for heterologous expression
of recombinant proteins, largely due to cost considera-
tions, speed, ease of use and genetic manipulation. But
for many proteins the bacterial cell often does not pro-
duce satisfactory results [3]. Obstacles to the efficient
expression of Plasmodium proteins in bacteria are their
usually high molecular weight (> 56 kDa), more basic pI
(> 6), lack of homology to bacterial proteins, Plasmo-
dium-specific inserts, often apparently disordered
sequences, transmembrane regions, signal peptides, dis-
ulphide bridges and export motifs [4-6]. In addition to
E. coli, several other organisms have, therefore, been
employed to attempt to improve heterologous expres-
sion, including baculovirus-infected insect cells [7]. This
system has the advantage of usually permitting produc-
tion of high molecular weight recombinant proteins,
with recognition of normal eukaryotic targeting signals
and post-translational machinery. However, the baculo-
virus expression system requires an increased invest-
ment time and uses higher cost media compared to
bacteria, and it is technically more challenging [3].
Producing recombinant proteins retaining natural
folding is essential for elucidating the three dimensional
structure of malaria proteins and for determining which
structural epitopes are exposed on the surface of IE dur-
ing natural malaria infections. Both bacteria and insect
cells have been shown to express Plasmodium proteins,
which retained conformational epitopes and elicited
antibody responses [8-10], and both systems have pro-
duced recombinant merozoite surface protein 1 (MSP1)
capable of acting as a protective immunogen and
capable of protecting mice and monkeys from malaria
challenge [11,12]. Existing data thus do not indicate that
one heterologous expression system is definitely superior
to the other and although bioinformatics tools can pre-
dict solubility and aid the design of suitable domains for
heterologous expression, such predictions are not
powerful and the identification of the optimal system
for heterologous expression remains a matter of experi-
mental testing.
The P. falciparum erythrocyte membrane protein 1
(PfEMP1) proteins are implicated in two key biological
phenomena in malaria; antigenic variation and sequestra-
tion [13,14], and have, therefore, been proposed as candi-
dates for a blood stage vaccine [15]. The PfEMP1 proteins
are encoded by the var gene family, with approximately 60
genes per haploid genome. Each gene consists of a highly
variable 5’ exon encoding an extracellular region and a sin-
gle transmembrane domain, a relatively conserved intron,
and a highly conserved 3’ exon encoding an intracellular
region of the transmembrane protein. The var genes vary
in size from 6 - 15 kb and encode PfEMP1 proteins
ranging in size from 200 - 500 kDa, the variable extracellu-
lar region being composed of several distinct domain
structures; the N-terminal segment (NTS, 75-100 aa),
Duffy-binding like domains (DBL, a-ε, 100-250 aa) and
the cysteine-rich interdomain (CIDR, a-g, 70-200 aa)
[2,16]. A few higher order arrangements of the domains
are conserved, such as the NTS-DBL1a-CIDR1a combi-
nation always found at the amino terminus (referred to
as the head structure) and the DBLδ-CIDRb/g tandem
pairing [17,18].
The high molecular weight of the full-length PfEMP1
proteins complicates full-length heterologous expression,
and the PfEMP1 proteins are usually expressed as single
or double domains. However, even though the size of
single domains are compatible with most expression sys-
tems, they still encompass biochemical and physical
characteristics, such as a high number of disulphide
bridges and a basic pI (> 6), that, in theory, make
recombinant expression difficult.
In previous studies [19,20], the parasite expression of
the PfEMP1 protein encoded by the var pfd1235w gene,
was found to be associated with severe childhood
malaria. However, the exact role of the PFD1235w pro-
tein during childhood malaria infections, including defi-
nition of the domain/motif binding host endothelium
ICAM1 and identification of immunodominant epitopes
remains to be established. Such studies require an
expression system producing experimentally useful
quantities of recombinant PFD1235w protein, with a
native fold. To address this issue, an E. coli and baculo-
virus expression system was used to express single and
double domains from the extracellular region of
the PFD1235w protein. The resulting proteins were
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evaluated in terms of yield and purity, ability to induce
antibodies reactive with native PFD1235w expressed on
the surface of IE and their recognition by Tanzanian
immune plasma.
Methods
Protein expression
The 3D7 DNA sequences encoding the PFD1235w pro-
tein domains listed in Additional file 1 was PCR ampli-
fied, cloned and expressed in a baculovirus insect cell
system as described [19,21,22]. Supernatants with
secreted recombinant protein were diafiltered on an
ÄKTAcrossflow (GE Healthcare) using Buffer A (20 mM
sodium phosphate, 500 mM sodium chloride, pH 7.5)
plus 10 mM imidazole prior to purification on a HIS-
select Cartridge column (Sigma-Aldrich). Bound recom-
binant protein was eluted using a one-step procedure
and Buffer A including 200 mM imidazole. Following
dialysis against buffer A the final protein concentration
was measured at UV280 nm.
Similarly, 3D7 pfd1235w DNA sequences (Additional
file 1) were PCR amplified and cloned in the E. coli
pET101/D-TOPO vector by blunt-end ligation, recombi-
nant plasmid transfected into the Rosetta-gami B (DE3)
E. coli strain with improved cytoplasmic disulphide bond
formation (Novagen) and protein expressed in 2x YT
media (1.6% (w/v) Bacto tryptone, 1% (w/v) yeast extract,
0.5% NaCl, pH 7.5) using the Champion™ pET Direc-
tional TOPO® Expression Kit as described (Invitrogen).
In brief, following dilution (1:100) of overnight cultures
cells were grown to OD600= 1 at 16-21°C and induced
with 10-1000 μM IPTG for 20 hours. Prior to large scale
protein production the optimal IPTG concentration and
temperature for induction of protein expression from
each construct was determined in a pilot experiment
using 10, 100, 1000 μM IPTG and incubating at 37°C for
3 hours, room temperature for 20 hours, and 4°C for 20
hours. The different IPTG concentrations only yielded
minor differences in expression levels and in most cases
10 μM was used for large scale protein production. Simi-
larly, varying the temperature only had a slight impact on
expression levels with incubation at room temperature
for 20 hours giving the highest yield. Following harvest-
ing, cell pellets were resuspended in 20 ml Buffer A plus
10 mM Imidazole and a Complete Mini Protease Inhibi-
tor Tablet without EDTA (Roche). Following sonication,
centrifugation and filtration supernatants were purified
on a HISTrapHP column (GE Healthcare). Elution, dialy-
sis and estimation of protein concentration was carried
out as described above.
SDS-PAGE and Western blotting
For purity and quality estimation 2 μg of each purified
recombinant protein, both reduced (+DTT) and non-
reduced (- DTT), was separated on a NuPAGE® Novex
4-12% Bis-Tris gel in MOPS SDS Running buffer (Invi-
trogen) and detected using BioSafe coomassie stain
(BIO-RAD). ProSieve Color Protein marker (Lonza) was
used for calibration and Quantity One software (BIO-
RAD) for protein quantification and size estimation.
Western blotting was done using standard techniques.
In brief, 0.2 μg purified protein was separated, blotted
onto a Hybond™-C Extra membrane (Amersham BioS-
ciences), and detected by an anti-V5-HRP antibody
(Invitrogen) using a Chemiluminescent detection kit
(Pierce).
Plasma samples
The plasma samples were obtained during a cross-sec-
tional survey in April 2001 as part of a longitudinal
study characterizing malaria morbidity and immunity
among individuals living in Mgome, Ubiri, and
Magamba village in the Tanga region of Northeastern
Tanzania. The point prevalence of P. falciparum in the
three different villages was 81% (Mgome), 41% (Ubiri),
and 12% (Magamba) [23]. Prior to this study, informed
consent was obtained from all studied individuals and/
or their parents and ethical clearance was granted by
the Ministry of Health and the Ethics Committee
(National Institute for Medical Research, Tanzania). For
this study, 15 samples from each of four predefined age
groups (2-4, 5-9, 10-14, and 15-19 years) were randomly
picked and used for Luminex plex analysis of antibody
reactivity to purified recombinant insect cell and E. coli
produced proteins. All plasma samples represented indi-
viduals with a previous history of malaria, but no clinical
symptoms at the time of sampling. Samples from 20
Danish donors with no previous exposure to malaria
were included as controls.
Luminex
The antibody reactivity of human plasma samples were
tested in the BioPlex100 System (BioRad) as previously
described [24]. Briefly, 50 μg of six insect cell (DBL1a-
CIDR1a, CIDR1a, DBL3b, DBL4g, DBL5δ, DBL5δ-
CIDR2b) and two E. coli (DBL3b, DBL4g) produced
proteins were individually coupled to 6.25 × 106 Lumi-
nex xMAP technology microsphere beads (Ramcon).
Diluents used were PBS/TB (PBS, 0.05% (v/v) Tween-20,
0.1% (w/v) BSA, pH 7.4). Prior to multiplexing, protein
coupling was verified by incubating 1250 coupled beads
with 1:100 to 1:1000,000 mouse anti-V5 antibody (Invi-
trogen) followed by biotinylated anti-mouse IgG (1:1000,
DakoCytomation). The biotinylated antibody was
detected using PE-streptavidin (1:1000, Invitrogen). Mul-
tiplexed beads (1.88 × 104 per protein per well) were
incubated with 180 different individual Tanzanian
plasma samples (1:1300) followed by PE-conjugated
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anti-human IgG (1:3200, Jackson Immunoresearch).
Beads were resuspended in 100 μl diluents and a mini-
mum of 100 beads from each set of multiplexed beads
were analyzed to yield the mean fluorescence intensity
(MFI). To test for inter-plate variation, each plate
included a pool of positive plasma titrated 2-fold from
1:40 to 1:20,480 in addition to a negative buffer control.
Antibody reactivity of individual plasma samples was
calculated as MFIsample minus MFIbuffer. For each of the
proteins the PBS buffer corrected mean MFI value plus
three standard deviations obtained with plasma from 20
Danish blood donors without previous exposure to
malaria was used as a negative cut-off value.
Generation of antisera
All procedures complied with European or national reg-
ulations. Prior to immunization each animal was pre-
bled and these sera were used as negative controls. Poly-
clonal rat antisera (2-3 rats per protein) were raised by
subcutaneous injection of 25 μg recombinant protein in
complete Freund’s adjuvant followed by several boosters
of 15 μg protein in incomplete Freund’s adjuvant. Addi-
tional bleeds were collected during and following the
completion of the immunization scheme.
Blocking of antibodies
Rat PFD1235w DBL1a-CIDR1a, DBL3b, DBL4g antisera
binding was blocked by incubation for 1 hr at 4°C using
excess purified recombinant homologous or heterolo-
gous produced protein (100 μl of 0.1 mg/ml protein in
each well containing 5 μl rat serum) and remaining anti-
body reactivity to native PFD1235w expressed on the
surface of 3D7PFD1235w infected erythrocytes was subse-
quently tested by flow cytometry as described below.
The resulting reduction in serum reactivity was calcu-
lated as ((MFIsample - MFImin)/MFImax)*100% with MFI-
min being the signal obtained with addition of secondary
antibody, but no antiserum and MFImax the signal
obtained with addition of serum and secondary anti-
body, but no blocking protein prior to testing by flow
cytometry.
Malaria parasite cultivation and in vitro selection
procedure
The P. falciparum 3D7 clone was cultured in blood
group 0 erythrocytes as previously described [25]. Cul-
tures were routinely genotyped by PCR using primers
targeting the polymorphic loci MSP2 and GLURP as
described [26], and mycoplasma tested using the
MycoAlert® Mycoplasma Detection Kit (Lonza) following
the manufactures instructions. IgG from rabbits immu-
nized with DBL4g of 3D7 PFD1235w expressed in insect
cells were used to in vitro select a previously selected
3D7 line [27]. Briefly, the rabbit sera were depleted on
human uninfected erythrocytes type 0, incubated with
gelatine purified trophozoite-stage 3D7 parasites for 30
min at 37°C, and unbound antibodies were removed by
washing. Subsequently, IE were incubated with Protein
A-coupled Dynabeads® (Invitrogen) for 30 min at 37°C
and bound IE were trapped using a magnet. Trapped IE
were transferred to new culture flasks for continued in
vitro culturing and the procedure was repeated until
cultures stained positive by the selecting antisera in flow
cytometry.
Flow cytometry
Flow cytometry surface staining was done with minor
modifications as described in Staalsoe et al., 1999 [25].
Briefly, IE were purified on a magnet-activated cell sort-
ing column (MACS), adjusted to 2 × 106 cells/ml and
100 μl cells were added to each well of 96 well plates
and incubated for 30 min at 4°C with 5 μl rat sera
depleted of anti-human erythrocyte antibodies. Follow-
ing, IEs were incubated for 30 min at 4°C with 100 μl/
well FITC-conjugated goat anti-rat IgG (Zymed) diluted
1:150 in PBS supplemented with 2% foetal calve serum
and ethidium bromide added to a final concentration of
2 μg/ml. IEs were analysed on a Cytomics FC 500 MPL
flow cytometer (Beckman Coulter), and data analysed
using WinList version 6.0 (Verity Software House Inc.).
IEs were gated based on the ethidium bromide staining
to exclude non-infected erythrocytes. Mean fluorescent
intensity (MFI) for individual rat bleeds were related to
MFI for the corresponding pre-bleed sample (MFI
bleed/MFI pre-bleed), and the sample with the highest
relative MFI value for each animal or each immuniza-
tion group were used for further analysis. A relative
MFI value of 1.3 was used as cut-off for discriminating
between positive and negative serum samples
Confocal microscopy
Laser scanning confocal microscopy was performed on
samples analysed by flow cytometry in order to observe
the staining patterns on individual IE. MACS purified
unlabelled infected cells from the same batches of para-
sites tested by flow cytometry were incubated with indi-
vidual antibodies as previously described [28]. Briefly, 1
μl packed IE were washed in three times in 100 μl 1%
BSA in PBS (BSA/PBS) and the pellet was incubated in
100 μl BSA/PBS and 3 μl of the respective antibodies
for 30 minutes at 4°C. The IE were washed three times
in BSA/PBS. The IE stained with primary antibody were
then incubated with 100 μl secondary antibody Alexa
488® anti-rat IgG (Invitrogen) and DAPI (3 μl of a 300
ng/ml solution) for 30 minutes at 4°C. The IE were
washed three times in 100 μl 1% BSA/PBS and visua-
lized as live, unfixed cells using a Nikon TE 2000-E con-
focal Nikon microscope with 60× oil immersion
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objective lens (DIC). The images were processed using
Adobe Photoshop software and displayed with the 5 μm
scale bar calculated by the EZ-C1 software.
Results
Yield and purity of recombinant PFD1235w protein
Seven constructs encoding single or double domains
from the extra-cellular region of the PfEMP1 protein
encoded by pfd1235w were made for experimental com-
parative expression in both insect cells and an E. coli
system. Successful expression and purification was
achieved with all seven constructs in baculovirus-
infected Trichoplusia ni High-5 cells (DBL1a-CIDR1a,
CIDR1a, DBL2b, DBL3b, DBL4g, DBL5δ-CIDR2b,
DBL5δ). Three out of seven constructs (CIDR1a,
DBL3b, DBL4g) produced detectable recombinant pro-
tein in the Rosetta-gami B (DE3) E. coli strain, which
has improved cytoplasmic disulphide bond formation
(Figure 1). All recombinant proteins were purified and
checked by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis and Western blotting as described pre-
viously (Figure 2) [19].
Five insect cell-derived proteins were processed to a
purity greater than or equal to 80%, whereas similar
purity was only achieved with one bacterial expressed
domain, DBL4g (Figure 1). The highest protein yield
observed was achieved with the DBL3b in insect cells
(app. 15 mg/L) with E. coli yielding a maximum of 11
mg/L for the DBL4g domain. With regards to estimating
the molecular weight of the products, in comparison
with the calculated expected molecular weight a 20%
average increase was observed when expressing protein
domains in insect cells. This was opposed to an average
of 12% increase observed in the E. coli expression sys-
tem (Figure 2). This 8% difference in size is explained
by glycosylation of the secreted recombinant protein
expressed by the insect cells. Degradation of the
PFD1235w domains was more pronounced in the E. coli
expression system with only DBL4g showing no sign of
degradation (Figure 2). By contrast, DBL1a-CIDR1a,
DBL4g, DBL5δ-CIDR2b, and DBL5δ expressed in the
baculovirus system were purified with no detectable
degradation (Figure 2). In addition to this, three addi-
tional proteins DBL1a, NTS-CIDR1a, and CIDR2b were
Figure 1 The structure and characteristics of PFD1235w. (A) Domain structure of PFD1235w with amino acid domain boundaries indicated.
Recombinant PFD1235w protein domains produced in (B) baculovirus-infected insect cells (solid lines) and (C) E. coli (dotted lines). (D) Purity (%),
(E) yield (mg/ml), (F) table of theoretical and observed molecular weight in kDa of insect cell and E. coli produced domains. Lines ending with a
diamond in (B) and (C) indicates recombinant protein inducing IE surface reactive antibodies in rats and (*) constructs tested by Luminex. NM:
not measured, NA: not applicable, NP: not produced.
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attempted expressed in insect cells, but not in E. coli. Of
these proteins only DBL1a failed to express.
Recombinant PFD1235w protein induces IE surface
reactive antibodies following immunization
Identification of surface-exposed PfEMP1 domains
accessible to antibodies has often been hampered by dif-
ficulties in generating specific surface-reactive anti-
PfEMP1 antibodies when using recombinant antigen as
the immunogen. To address this issue for the particular
PfEMP1 of interest, that associated with severe malaria
in children [19], rats were immunized with recombinant
PFD1235w protein domains expressed in insect cells
(NTS-CIDR1a, DBL1a-CIDR1a, CIDR1a, DBL2b,
DBL3b, DBL4g, DBL5δ-CIDR2b, DBL5δ, CIDR2b) or E.
coli (DBL1a-CIDR1a, CIDR1a, DBL3b, DBL4g).
Flow cytometry was used to test the ability of the
induced antisera to recognize native PFD1235w on the
surface of erythrocytes infected with a 3D7PFD1235w
parasite line selected for expression of high levels of this
particular PfEMP1 [19]. Antisera raised against all the
insect-cell produced domains were surface reactive with
the 3D7PFD1235w line, except antisera to CIDR2b (Figure
1, Figure 3A, and Figure 4). In contrast, only antisera
raised against DBL4g produced in the E. coli Rosetta-
gami B (DE3) strain contained IgG surface reactive with
the surface of 3D7PFD1235w as did DBL1a-CIDR1a anti-
sera although this protein did not express at detectable
levels (Figure 1 and Figure 3A).
This demonstrates that the majority of the seven dif-
ferent domains are surface-exposed and accessible to
antibodies on the surface of infected human erythrocytes
that are expressing the PFD1235w PfEMP1 antigen
(Figure 4). An increased reactivity to the surface of
infected erythrocytes was observed with antisera target-
ing the C-terminal parts of PFD1235w as compared to
sera targeting the N-terminal regions of this PfEMP1,
irrespective of the production system (Figure 3B).
Sharing of epitopes between insect cell and E. coli
produced PFD1235w protein
To compare the antibody epitope profile being exposed
by insect cell and E. coli produced protein domains, rat
antisera raised against the recombinant constructs was
blocked by homologous as well as heterologous protein
prior to flow cytometry testing (Figure 5). Both homolo-
gous and heterologous DBL4g removed all IE surface
antibody reactivity of both the heterologous and
Figure 2 Purity of recombinant PFD1235w protein domains expressed in insect cells and E. coli. (A and C) Sodium dodecyl sulfate-
polyacrylamide (SDS-PAGE) gel electrophoresis of 2 μg/lane and (B and D) Western blotting of 0.2 μg/lane recombinant protein. (A and B) Insect
cell produced protein (1-2) NTS-CIDR1a, (3-4) DBL1a-CIDR1a, (5-6) CIDR1a, (7-8) DBL2b, (9-10) DBL3b, (11-12) DBL4g, (13-14) DBL5δ-CIDR2b,
(15-16) DBL5δ, (17-18) CIDR2b and (C and D) E. coli produced (1-2) DBL1a-CIDR1a, (3-4) CIDR1a, (5-6) DBL2b, (7-8) DBL3b, (9-10) DBL4g, (11-12)
DBL5δ-CIDR2b, (13-14) DBL5δ. M: ProSieve Color Protein marker (Lonza). Samples were reduced using DTT (+) or non-reduced (-). Arrows indicate
identified protein band.
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homologous anti-DBL4g antisera (Figure 5B1 and 5B2)
indicating that the two proteins are similarly folded and
expose identical epitopes.
Similarly, E. coli produced DBL3b removed the surface
antibody reactivity of the heterologous antisera, although
this protein was unable to induce surface reactive anti-
bodies in rats (Figure 5C). By contrast, the baculovirus
produced DBL1a-CIDR1a was unable to block the reac-
tivity of antisera raised against the heterologous protein.
This indicates that there is a difference in the antibody
epitopes being exposed in the rats following immuniza-
tion (Figure 5A1 and 5A2). Doubling the concentration
of blocking protein gave similar results. However, deple-
tion using E. coli produced DBL1a-CIDR1a protein did
lead to a reduction in the reactivity of the heterologous
antisera (Figure 5A1).
Antibodies acquired during in vivo infections recognize
recombinant PFD1235w domains
A bead-based Luminex assay [24] was used to assess
antibody reactivity of plasma samples from 180 Tanza-
nian children with a previous history of malaria [29] and
20 Danish blood donors with no previous exposure to
malaria (Figure 6).
The average mean fluorescent intensity (MFI) of the
antibody reactivity of the Danish control plasma samples
towards the six insect cell produced proteins (DBL1a-
CIDR1a, CIDR1a, DBL3b, DBL4g, DBL5δ, DBL5δ-
CIDR2b) was low (MFIaverage= [29;80], MFImin= [0;5],
MFImax=[84;349]) compared to the antibody reactivity to
the bacterial produced DBL3b (MFIaverage= 151, MFI-
min= 6, MFImax= 525) and DBL4g (MFIaverage= 351, MFI-
min= 4, MFImax= 1042) domains. This probably reflects
naturally acquired antibodies reacting with host con-
taminants present in the batch of DBL3b and DBL4g
produced in the E. coli system. As a result of this reac-
tivity the MFI cut-off value based on the reactivity in
Danish plasma was higher for the E. coli proteins than
for the insect cell produced PfEMP1 domains.
A relationship between transmission intensities, age
groups and percentage of responders was observed for
all eight recombinant PfEMP1 domains (Figure 6). The
plasma antibody reactivity also increased with age and
with increasing transmission intensity. However, the two
Figure 3 IE surface reactivity of sera raised against insect cell and E. coli produced domains of PFD1235w. (A) IE surface reactivity of rat
antiserum raised against recombinant PFD1235w as indicated in the legend and measured by flow cytometry. (B) Antibodies against C-terminal
located PFD1235w domains show higher IE surface reactivity than antibodies against N-terminal domains. Circles and triangles in (B) show
antibody reactivity of plasma from rats immunized with insect cell and E. coli produced domains, respectively. Two-three rats were immunized
with different PFD1235w domains and plasma was obtained as described in the Methods section. Antibody reactivity to infected erythrocytes
surface expressing PFD1235w was measured by flow cytometry and data given as MFI sample/MFIsample prebleed. The dotted line shows the cut-off
defined as described in the Methods section.
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Figure 4 IE surface reactivity of sera raised against insect cell produced domains of PFD1235w. Shown is flow cytometry of PFD1235w
expressing IE labelled with PFD1235w domains-specific rat antisera (green histograms) or with preimmunization control sera (grey histograms).
The corresponding immunofluorescence microscopy surface reactivity is shown by inserts for antisera against CIDR1a, DBL3b, DBL4g, DBL5δ and
DBL5δ-CIDR2b. Preimmunization sera and antisera against VAR2CSA [37] were negative in both assays.
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Figure 5 Recognition of native PFD1235w expressed on the surface of 3D7PFD1235w IE. The surface antibody reactivity of rat antisera raised
against (A1 and B1) insect cells and (A2 and B2) E. coli produced DBL1a-CIDR1a and DBL4g was measured by flow cytometry. (C) The antibody
surface reactivity of rat antisera raised against insect cell produced DBL3b. Antisera were pre-incubated with excess homologous immunizing
protein, heterologous produced protein, PBS or irrelevant protein as indicated. The percentage of reactivity left following depletion was
calculated as described in the Methods section.
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bacterial produced proteins showed a lower percentage
of positive responders compared to the homologous
insect cell produced proteins. Of the 180 Tanzanian
plasma samples 75% were either both positive or both
negative in reactivity to insect cell and E. coli produced
DBL3b and 65% both positive or both negative for
DBL4g. The number of plasma samples showing positive
antibody reactivity to insect cell produced, but not E.
coli produced protein was markedly higher than the
opposite situation (DBL3b: 22% vs 3%, DBL4g: 32% vs
2%).
Discussion
Identification of heterologous expression systems cap-
able of expressing milligrams of soluble recombinant P.
falciparum protein is a challenging process. In this
study, the use of E. coli and insect cells were compared
in producing 44-93 kDa single- and double protein
domains encoded by the pfd1235w var gene. All seven
constructs introduced into the baculovirus expression
system produced recombinant protein, while three of
seven constructs produced protein in the prokaryotic
system (Figure 1). The high molecular weight (≥ 57
kDa) of the four remaining E. coli constructs might
explain why these did not express [4-6]. Decreasing the
expression temperature to 4°C or varying concentrations
of IPTG did not result in improved expression (data not
shown).
Plasmodium falciparum proteins that are expressed in
insoluble inclusion bodies in bacteria have previously
been shown to be expressed in soluble form and capable
of being made and purified in milligram amounts upon
transfer to the baculovirus system [4]. However, the
baculovirus expression system has yet to prove its worth
when it comes to crystallography of PfEMP1 proteins,
since five out of the six published crystal structures to
date have been done on bacterially expressed recombi-
nant proteins [30-35]. In addition, insect cells are
known to sometimes hyper-glycosylate their recombi-
nant products, a potential problem for expression of
PfEMP1, as N- and O-glycosylations seem to occur at
very low levels in P. falciparum [36].
The insect cell produced proteins were between 60-
97% pure as compared to 3-95% for the E. coli proteins.
This difference can probably be ascribed to the fact that
the insect cell expressed proteins are purified from the
cell media, as opposed to the bacterially expressed pro-
tein, which were purified from total cell extract. Degra-
dation and co-purification of degradation products was
observed with both expression systems, but was espe-
cially evident in the E. coli expression system. In addi-
tion, larger bands were visible in non-reducing lanes on
Western blots for all the expressed recombinant pro-
teins, possibly representing dimers and trimers.
Flow cytometry was used to test the ability of antisera
to recognize native PFD1235w on the surface of erythro-
cytes infected with 3D7PFD1235w a parasite line selected
for high surface expression of PFD1235w [19]. Antisera
raised against all of the seven baculovirus proteins and
against PFD1235w DBL4g and DBL1a-CIDR1a domains
produced in the Rosetta-gami B (DE3) E. coli strain
showed IgG reactivity with the surface 3D7PFD1235w. In
contrast to a previous study [37], this also showed the
ability of the E. coli expression system to produce
PfEMP1 protein domains with a three-dimensional
structure sufficiently resembling that of the native
Figure 6 Human antibody reactivity to PFD1235w. Percentage antibody responders to recombinant PFD1235w domains produced in
baculovirus-infected insect cells (A1-C1) and in E. coli (A2-C2). The antibody reactivity of plasma obtained from individuals living in three
Tanzanian villages (A) Magamba, (B) Ubiri, and (C) Mgome of low, moderate, and high malaria transmission intensity was measured by Luminex.
Each age group (2-4, 5-9, 10-14, and 15-19 years) included 15 individuals. The percentage responders was categorized into six different intervals:
0-15 (white), 16-30 (lighter gray), 31-45 (light gray), 46-60 (dark grey), 61-75 (darker grey), and >76 (black).
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molecule to induce surface reactive antibodies following
experimental immunization.
The insect cell produced DBL4g consistently induce
surface reactive IgG in rats, whereas this is not always
observed with recombinant DBL4g expressed by E. coli.
This would indicate the E. coli expression system to be
more sensitive to batch to batch variation.
To assess similarities in exposed antibody epitopes
homologous and heterologous antisera were pre-incu-
bated with recombinant DBL4g, DBL3b and DBL1a-
CIDR1a produced in both expression systems prior to
testing by flow cytometry (Figure 5). The two DBL4g
domains exposed identical epitopes as the reactivity of
the antisera raised against insect cell produced DBL4g
could be abolished by pre-incubating with E. coli pro-
duced DBL4g and vice versa (Figure 5B1 and 5B2). Simi-
larly, DBL3b produced in E. coli abolished the reactivity
of the heterologous antisera following depletion although
this protein did not induce surface reactive antibodies
following immunization of rats. However, this was not
the case for the DBL1a-CIDR1a antisera indicating that
the insect and bacterial derived proteins were fundamen-
tally different due to differences in folding and/or post-
translational modifications. These results show that most
PFD1235w domains are surface exposed and accessible
to antibodies in the native molecule as expressed by IE
and that induction of surface reactive IgG seem critically
dependent on a correct three-dimensional structure of
the antigen used for immunization, a structure which is
more often achieved in the eukaryotic compared to the
prokaryotic system used. Depletion of DBL1a-CIDR1a
and DBL5δ-CIDR2b antisera using either CIDR1a,
DBL5δ or CIDR2b protein produced in insect cells show
a reduced reactivity by FACS. This strongly indicates
DBL1a and CIDR2b to be similarly exposed on the native
PFD1235w exported to the surface of IE.
Six of the seven insect cell and two of the E. coli pro-
duced proteins were used in a bead based Luminex
assay to assess the antibody reactivity of 180 plasma
samples collected from individuals with a previous expo-
sure of malaria and living in a high (Mgome), moderate
(Ubiri), and low (Magamba) malaria transmission area
of Tanzania [23]. The MFIcut-off value for the bacterial
derived proteins in the Luminex analysis was consider-
able higher than their homologous counterparts from
the baculovirus expression system. This cannot be
explained by reactivity against the V5 tag as all proteins
irrespective of expression system carry this, but is more
likely a consequence of the low purity of the bacterial
recombinant proteins samples.
Although the E. coli produced DBL3b did not induce
any surface reactive antibodies in rats both domains
were recognized by African sera in the Luminex assay.
However, at a reduced level as compared to the
equivalent insect cell produced protein (Figure 6). All
proteins irrespective of production system were recog-
nized by plasma antibodies in an age and transmission
dependent manner. This correlation between malaria
transmission intensity, age and acquisition of antibodies
is in line with our previous finding on antibody
responses to PFD1235w [20].
Conclusions
This study, assessed the use of a eukaryotic and prokar-
yotic system for expression of PFD1235w protein and
found the insect cells more reliable and superior to
E. coli in producing recombinant PfEMP1 domains that
generates IE surface reactive antibodies following immu-
nization of rats.
Additional material
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primers used for PCR amplification of amplicons encoding different
PFD1235w protein domains.
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